NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.  The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Robin L. Smith
Chairman & CEO, M.D., MBA

Larry A. May
Chief Financial Officer

Catherine M. Vaczy
Vice President and General Counsel

Alan G. Harris
M.D., Ph.D.-- Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs

Anthony Salerno
Vice President, Strategic Development and Academic Affairs

Jason Kolbert
Vice President of Strategic Business Development, MBA

Andrew L. Pecora
Chief Medical Officer, Progenitor Cell Therapy, M.D., F.A.C.P.

George S. Goldberger
Vice President – Business Development, Progenitor Cell Therapy

Robert A. Preti
President and Chief Scientific Officer, Progenitor Cell Therapy, Ph.D.

Daryl LeSueur
Vice President - Manufacturing Operations, Progenitor Cell Therapy, BSc